<?xml version="1.0" encoding="UTF-8"?>
<results title="funders">
 <result pre="Lily 14 [1], [2], grid.419971.3 Drug Product Science and Technology," exact="Bristol-Myers Squibb" post="Company, [3], 0000 0004 0472 2713 grid.418961.3 Formulation Development,"/>
 <result pre="Large Molecule Drug Product Development, Janssen Research &amp;amp; Development, LLC," exact="Johnson and Johnson," post="[5], [6], 0000000122986657 grid.34477.33 Department of Bioengineering, University of"/>
 <result pre="Johnson and Johnson, [5], [6], 0000000122986657 grid.34477.33 Department of Bioengineering," exact="University of Washington," post="[7], 0000 0000 8800 7493 grid.410513.2 Biotherapeutics Pharmaceutical Sciences,"/>
 <result pre="Pfizer, [8], 0000 0001 2179 3263 grid.418574.b Pharma Excipients, The" exact="Dow Chemical Company," post="[9], 0000 0001 0657 5612 grid.417886.4 Process Development, Amgen,"/>
 <result pre="Amgen, Inc., [10], 0000 0004 0413 7987 grid.417882.0 Pharmaceutical Development," exact="Allergan" post="Inc., [11], 0000 0004 0534 4718 grid.418158.1 Late Stage"/>
 <result pre="[12], 0000 0000 2220 2544 grid.417540.3 Bioproduct Research &amp;amp; Development," exact="Eli Lilly and Company," post="[13], 0000 0001 2264 7145 grid.254250.4 Department of Chemical"/>
 <result pre="This size range will likely gain more attention as the" exact="U.S. Food and Drug Administration" post="Guidance for Immunogenicity Assessment for Therapeutic Protein Products states"/>
 <result pre="size range will likely gain more attention as the U.S." exact="Food and Drug Administration" post="Guidance for Immunogenicity Assessment for Therapeutic Protein Products states"/>
 <result pre="differences in refractive index between particle and surrounding solution. The" exact="National Institute of Standards and Technology" post="(NIST) has done extensive studies comparing these methods to"/>
 <result pre="Progress in amorphous food and pharmaceutical systems 2002 London The" exact="Royal Society" post="of Chemistry 200 215 41. Piedmonte DM Summers C"/>
 <result pre="Crommelin D Methods for structrual analysis of proteins 2005 Arlington" exact="American Association of Pharmaceutical Scientists" post="80. Zolls S Tantipolphan R Wiggenhorn M Winter G"/>
 <result pre="Pharm Sci 2009 98 4 1246 1277 18683878 84. US" exact="Department of Health" post="and Human Services, Food and Drug Administration. Guidance for"/>
 <result pre="1277 18683878 84. US Department of Health and Human Services," exact="Food and Drug Administration." post="Guidance for Industry: Immunogenicity assessment for therapeutic protein products."/>
 <result pre="for Industry: Immunogenicity assessment for therapeutic protein products. Silver Springs:" exact="U.S. Department of Health and Human Services," post="FDA, CDER, CBER; 2014. 85. Tian X Nejadnik MR"/>
 <result pre="Industry: Immunogenicity assessment for therapeutic protein products. Silver Springs: U.S." exact="Department of Health" post="and Human Services, FDA, CDER, CBER; 2014. 85. Tian"/>
</results>
